Dinutuximab is ahuman/mouse chimeric monoclonal antibody of isotype IgG1 that targets GD2. GD2 is a disialoganglioside expressed on neuroectodermal tumors, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. By binding to GD2, dinutiximab induces apoptosis and inhibits the proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), to treat childrens with high-risk neuroblastoma.
There are no reviews yet.
Your email address will not be published. Required fields are marked *
In which application did you use the antibody? *
Did it work in your application? *
Your review *
Save my name, email, and website in this browser for the next time I comment.
Send us a message from the form below
Lab / Company
in 2023, NO price increase on ProteoGenix products, to support your discoveries💥